Articles from CancerVAX, Inc

The Company's scientific team describes how they successfully disguised cancer cells and tricked immune cells into attacking them and reveals the next phase of their development plan

Recent lab results proved the Company’s hypothesis that disguising cancer cells to look like common infectious diseases can trick immune cells into attacking the malignant cells

In-vitro lab results confirmed that the Company’s cell targeting nanoparticles successfully entered cancer cells and avoided non-cancerous cells

Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program

Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells

Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology

Dr. Sumant Ramachandra to advise the Company about the development of its revolutionary cancer treatment

Recent in-vitro lab results confirm that the Company’s proprietary Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells

With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors

Dr. George Katibah to serve as the Company’s Chief Scientific Officer

Research Agreement Leverages Structural Nanomedicine to Develop CancerVax’s Advanced Cancer Therapies

New Smart mRNA Technology will kill cancer cells by making them look like common and easy to treat diseases such as measles or chickenpox

Dr. Jonathan Lakey will serve as Chief Scientific Advisor and Dr. Adam Grant will serve as Principal Scientist

The UCLA research team created a low cost and customizable lipid nanoparticle using “click chemistry” for precise targeting of cancer cell surface markers

Company plans to launch FDA IND enabling studies needed to apply for approval to proceed with human trials

Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments

Two oncology executives discuss the challenges and need for continued development in the cancer space.

The Company’s development pipeline now includes three projects with UCLA

Foundational technology developed by UCLA for the Company’s Universal Cancer Vaccine can be adapted to function as an in-vivo CAR-T cell platform to dramatically lower the cost of CAR-T cell cancer therapies

Dr. Steven Jonas commented about his journey to becoming both a practicing cancer doctor and active cancer researcher

Dr. Lakey has been recognized nationally and internationally for his groundbreaking research in cell and tissue transplantation for patients suffering from diabetes and cancer

The two industry leaders focus on navigating the biotech industry and immuno-oncology research

Three separate teams of physician scientists at UCLA working on three different parts of the project have made significant progress and are ready to merge their work into a complete proof-of-concept vaccine construct

Michael Smith comments on the growth of immunotherapy and sees the required FDA development phases as a benefit to small biotech firms such as CancerVax

Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatments

UCLA research team has successfully created 7 pre-clinical monoclonal antibody candidates for targeting Ewing sarcoma

University Partnerships: The Secret Weapon in Cancer Therapeutics Innovation

LEHI, Utah, May 17, 2023 (GLOBE NEWSWIRE) -- CancerVAX, developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today reported that the Company’s CEO, Ryan Davies, recently discussed the importance of developing new drugs and medical devices and their impact on the world of healthcare with biotech entrepreneur and venture capitalist Dinesh Patel.

Stephen Diamond, Senior Vice President, General Counsel, and Secretary of Freeline, discussed his unique path from the legal and business worlds to gene therapy and next-generation therapeutics.

Dr. Satiro De Oliveira, a principal investigator in the Company’s cancer research program at UCLA, comments about the importance of cancer immunotherapy

Experienced business executive to help establish the Company as a significant force in the field of cancer research

Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX CEO Ryan Davies to discuss the future of novel therapeutics and how the industry can encourage young scientists to enter the field.

Dr. Jonathan Lakey, Professor in University of California – Irvine’s Surgery and Biomedical Engineering departments, spoke with CancerVAX CEO Ryan Davies on his accomplishments in scientific research and their impact on the world

Dr. David Bearss, an oncology researcher and biotech start-up founder, spoke with CancerVAX CEO Ryan Davies on the future of oncology therapeutics

The UCLA research team, which includes Dr. Steven Jonas, Dr. Christopher Seet, Dr. Satiro De Oliveira and Dr. Christopher Denny, will leverage cutting-edge technologies to develop a breakthrough universal cancer vaccine (UCV) that will train the body to target and destroy cancer cells.

The Company’s patent application describes how it plans to leverage cutting-edge CRISPR and mRNA technologies to develop a breakthrough universal cancer vaccine (UCV)